



Universiteit
Leiden
The Netherlands

Oxidation, aggregation and immunogenicity of therapeutic proteins

Torosantucci, R.

Citation

Torosantucci, R. (2013, September 17). *Oxidation, aggregation and immunogenicity of therapeutic proteins*. Retrieved from <https://hdl.handle.net/1887/21762>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/21762>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/21762> holds various files of this Leiden University dissertation.

Author: Torosantucci, Riccardo

Title: Oxidation, aggregation and immunogenicity of therapeutic proteins

Issue Date: 2013-09-17

Chapter 6

Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon beta-1a: potential implications for protein aggregation and immunogenicity

Riccardo Torosantucci^{1,2}, Victor S. Sharov², Miranda van Beers³, Vera Brinks⁴, Christian Schöneich² and Wim Jiskoot¹

¹Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, the Netherlands.

²Department of Pharmaceutical Chemistry of Kansas University, Lawrence, Kansas, USA.

³Bioprocessing Technology Institute, Agency for Science Technology and Research (A*STAR), Singapore.

⁴Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.

Molecular Pharmaceutics **2013**, *10*, 2311-2322.

Abstract

Oxidation via Cu^{2+} /ascorbate of recombinant human interferon beta-1a (IFN β -1a) leads to highly immunogenic aggregates, however it is unknown which amino acids are modified and how covalent aggregates are formed. In the present work we mapped oxidized and cross-linked amino acid residues in aggregated IFN β -1a, formed via Cu^{2+} /ascorbate catalyzed oxidation. Size exclusion chromatography (SEC) was used to confirm extensive aggregation of oxidized IFN β -1a. Circular dichroism and intrinsic fluorescence spectroscopy indicated substantial loss of secondary and tertiary structure, respectively. Derivatization with 4-(aminomethyl) benzenesulfonic acid was used to demonstrate, by fluorescence in combination with SEC, the presence of tyrosine (Tyr) oxidation products. High performance liquid chromatography coupled to electrospray ionization mass spectrometry of reduced, alkylated and digested protein was employed to localize chemical degradation products. Oxidation products of methionine, histidine, phenylalanine (Phe), tryptophan and Tyr residues were identified throughout the primary sequence. Covalent cross-links via 1,4- or 1,6-type addition between primary amines and DOCH (2-amino-3-(3,4-dioxocyclohexa-1,5-dien-1-yl) propanoic acid, an oxidation product of Phe and Tyr) were detected. There was no evidence of disulfide bridge, Schiff base, or dityrosine formation. The chemical cross-links identified in this work are most likely responsible for the formation of covalent aggregates of IFN β -1a induced by oxidation, which have previously been shown to be highly immunogenic.

Introduction

Recombinant human interferon beta (IFN β), a cytokine with anti-inflammatory and tumor-suppressor functions [1] is considered as the first choice treatment of multiple sclerosis, a severe neurodegenerative autoimmune disease [2]. Interferon beta-1a (IFN β -1a), in contrast to interferon beta-1b (IFN β -1b) [3], is glycosylated at asparagine 80 [4] carrying mainly biantennary and triantennary glycan structures [5-6]. IFN β -1a has an average molecular weight of about 22.5 kDa, contains 166 amino acid residues and is produced in Chinese hamster ovarian (CHO) cells [6]. As described by Karpusas et al. [7], the protein contains five alpha helices, an intramolecular disulfide bridge between cysteines in positions 31 and 141, and a free cysteine (Cys) in position 17.

Like many other protein therapeutics, IFN β is prone to aggregation, which has been correlated with enhanced immunogenicity [8]. Furthermore, it has been demonstrated that the removal of protein aggregates reduces the immunogenicity of IFN β formulations [9-11]. In addition, IFN β -1b (Betaferon[®]), which contains more aggregates than IFN β -1a products (Avonex[®], Rebif[®]), has been found to be the most immunogenic IFN β product in several preclinical and clinical studies [12-13].

Protein aggregates induced by metal-catalyzed oxidation (MCO) have been found to be particularly immunogenic in preclinical models. For instance, Hermeling et al. showed that recombinant human interferon alpha-2b (IFN α -2b) forms immunogenic aggregates upon oxidative stress induced by Cu²⁺/ascorbate catalyzed oxidation, using a transgenic mouse model immune tolerant to the human protein [14-15]. Similarly, IFN β -1a aggregates and monoclonal antibody aggregates, both produced via the same oxidative system, were shown to be highly immunogenic in transgenic immune tolerant mouse models [8, 16]. We therefore believe that characterization of chemical modifications and cross-links caused by Cu²⁺/ascorbate catalyzed oxidation is of high importance, since these data may shed light on structure-immunogenicity relationships for IFN β -1a and potentially other therapeutic proteins.

The scope of the present work was to identify the chemical modifications in Cu²⁺/ascorbate oxidized IFN β -1a, including covalent cross-links that may be involved in aggregation. Here we report a comprehensive characterization of

oxidative modifications in IFN β -1a following MCO and discuss putative mechanisms of MCO-induced IFN β -1a aggregation. Our data strongly support the formation of electrophilic oxidation products, which can be further involved in aggregate formation via 1,4- or 1,6-type addition to pre-existing protein nucleophiles, such as primary amine groups, in agreement with our recent mechanistic studies on insulin as a model protein [17].

Materials and Methods

Materials

IFN β -1a (0.26 mg/mL protein in 20 mM sodium acetate buffer, pH 4.8, containing 154 mM arginine) was kindly provided by Biogen Idec Inc. (Cambridge, MA, USA). PNGase F, L-ascorbic acid, ethylenediamine tetraacetic acid (EDTA), copper dichloride, arginine, monobasic and dibasic sodium hydrogen phosphate, ammonium bicarbonate (ABI), sodium chloride, sodium azide, SDS, dithiothreitol (DTT), iodoacetamide, glacial acetic acid, and acetonitrile were purchased from Sigma–Aldrich (St.Louis, MO, USA). Milli-Q water was used for the preparation of all the formulations. All chemicals were of analytical grade and used without further purification. 4-(aminomethyl) benzenesulfonic acid (ABS) was synthesized according to a published procedure [18]. Endoproteinases Glu-C and trypsin were purchased from Promega (Madison, WI, USA).

Preparation of untreated and oxidized IFN β 1-a formulations

IFN β -1a was prepared and treated as reported by van Beers et al [8]. Briefly, the protein solution was dialyzed against 100 mM sodium phosphate buffer and 200 mM sodium chloride, pH 7.2 (PBS). This dialyzed solution is referred to as untreated IFN β -1a. To obtain oxidized IFN β -1a, untreated IFN β -1a, diluted to 200 μ g/mL with PBS, was incubated with 4 mM ascorbate and 40 μ M CuCl₂ for 3 hours at room temperature. The oxidation reaction was stopped by adding 100 mM EDTA to a final concentration of 1 mM as previously reported [17].

ABS derivatization

Untreated and oxidized protein (0.2 mg/mL) were dialyzed against 50 mM ABI, pH 8.0, using a 3.5-kDa MWCO Slide-A-Lyzer Cassette (Asheville, NC, USA), before derivatization with ABS. To 250 μ L of dialyzed samples 7.5 μ L of 0.1 M sodium hydroxide were added to adjust the pH to 9.5. Then 100 mM ABS stock solution was added to a final concentration of 10 mM. Subsequently, 5 mM K₃Fe(CN)₆ stock solution in Milli-Q water was added to a final concentration of 0.5 mM. The reaction was conducted for 1 hour at room temperature, before performing SEC analysis or fluorescence measurement (as reported below in the section Size exclusion chromatography and Fluorescence spectroscopy, respectively). Controls for non-specific fluorescence included (i) oxidized and non-oxidized protein prior to derivatization and (ii) reagents alone (i.e. ABS/K₃Fe(CN)₆) incubated under the same conditions.

Size exclusion chromatography

To determine the aggregate content and to investigate the effect of reducing agents on oxidized and untreated IFN β -1a, SEC was performed by using a TSKgel Super SW2000 column protected by a Super SW guard column (Sigma Aldrich, St. Louis, MO, USA). An SPD-6AV UV and fluorescence detector (Shimadzu, Columbia, MD, USA) was used to record the chromatograms at a wavelength of 280 nm and at excitation/emission wavelength combination of 295/350nm, respectively. A flow rate of 0.35 mL/min was applied using a 515 HPLC pump and 717 Plus autosampler (Waters, Milford, MA, USA). The mobile phase consisted of 200 mM sodium chloride, 0.05% (w/v) sodium azide and 0.1% (w/v) SDS in 100 mM sodium phosphate, pH 7.2, which was filtered through a 0.2- μ m filter prior to use.

To detect fluorescent benzoxazole products in the ABS-derivatized samples, we used an Insulin HMWP Column, 7.8 \times 300 mm (Waters) connected to a HPLC system (Shimadzu, Columbia, MD, USA) coupled with a Shimadzu RF-20A fluorescence detector. Excitation and emission wavelengths were set at 360 and 490 nm, respectively. The mobile phase composition and flow rate were as previously reported [19].

Fluorescence spectroscopy

The emission spectra of the ABS-derivatized samples, diluted two fold in ABI, were measured in a 0.5-mL quartz fluorescence cuvette with an RF-5000U fluorescence spectrophotometer (Shimadzu) with excitation and emission wavelengths range set at 360 and 400-600 nm, respectively, and bandwidths set at 5 nm.

To test the potential presence of dityrosine, fluorescence of the oxidized IFN β -1a was measured in triplicate, using excitation and emission wavelengths set at 315 and 420 nm, respectively, as described previously [20]. Tryptophan (Trp) intrinsic fluorescence was measured with a Tecan infinite M1000 fluorometer (Tecan group Ltd., Männedorf, Switzerland) upon excitation at 295 nm and emission recorded from 310-500 nm with a step size of 2 nm, 50 flashes (frequency 400 Hz), a gain of 150 and a Z-position of 20.0 mm. Duplicates of 200 μ L of each sample were analyzed in black polystyrene 96-well plates (Greiner Bio-One, Frickenhausen, Germany).

Circular dichroism spectroscopy

Circular dichroism (CD) spectra of untreated and oxidized IFN β -1a (0.1 mg/mL) were recorded from 190 to 250 nm, using a Jasco J-815 CD spectrometer (Jasco International, Tokyo, Japan). Analyses were performed in a 1-mm (far-UV CD) path length quartz cuvette at 25 °C using a scan rate of 100 nm/min, a response time of 2 s, and a bandwidth of 1 nm. Each spectrum was the result of an averaging of six repeated scans and background was corrected with the corresponding buffer spectrum. The CD signals were converted to mean residue ellipticity $[\theta]_{\text{mrw}, \lambda}$, using a mean residue weight (MRW, calculated as $\text{MRW} = \text{M}/(\text{N}-1)$, where M is the average molecular weight of the untreated (glycan-free) protein (i.e. 20027 Da, based on the protein's chemical formula $\text{C}_{908}\text{H}_{1408}\text{N}_{246}\text{O}_{252}\text{S}_7$) and N is the number of amino acid residues in the chain).

Reduction, alkylation and digestion

Untreated and oxidized protein (0.2 mg/mL) were dialyzed against 50 mM ABI, pH 8.0, using a 3.5-kDa MWCO Slide-A-Lyzer Cassette (Asheville, NC, USA), and reduced by addition of 50 mM DTT, freshly prepared in 50 mM ABI,

pH 8.0, to a final concentration of 5 mM. The samples were incubated for 45 minutes at 45 °C using a Thermo NES heating bath (Thermo Scientific, NC, USA). Subsequently, 200 mM iodoacetamide, freshly prepared in 50 mM ABI, pH 8.0, was added to a final concentration of 20 mM. The digestion was performed as follows: IFN β -1a was incubated with Glu-C endoproteinase at a IFN β -1a/Glu-C ratio of 10:1 (w/w), for 1 hour at 37 °C. Next, trypsin was added (IFN β -1a/trypsin ratio 20:1 (w/w)) and the mixture was incubated for an additional hour at the same temperature. Finally, 4 μ L of a solution of PNGase F, dissolved according to the manufacturer's protocol, was added to 76 μ L of the protein mixture, which was then incubated overnight at 37 °C.

MS/MS analysis

Digested and non-digested samples were analyzed by means of an LTQ-FT hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (Thermo-Finnigan, Bremen, Germany) [21]. The MS/MS spectra were analyzed with the web-based software MassMatrix [22-25], which was used to simulate mass spectra and the theoretical fragment tables of the b- and y-ions [26] for the native, oxidized and cross-linked peptide products. The simulated spectra were compared to the experimental MS/MS spectra in order to validate the proposed product and cross-link structures. A mass accuracy sensitive probability-based scoring algorithm for database searching of tandem mass spectrometry data by MassMatrix software was employed for peptide identification; the manual filter was set at mass/charge ratio (m/z) accuracy <0.1 amu for both parent peptide and fragment ions.

Results

Comparison of untreated and oxidized IFN β -1a by SEC and spectroscopic methods

SEC analysis was used to verify whether the aggregation profile of oxidized IFN β -1a was similar to that observed earlier [8] and to study a potential involvement of disulfide bridging in aggregate formation. Comparison of the chromatograms of untreated and oxidized IFN β -1a (Figure 1A) shows extensive aggregation of the oxidized product and both chromatograms are in close agreement with the results published by van Beers et al [8].

Furthermore, the treatment of oxidized IFN β -1a with DDT did not have a major impact on the elution behavior, indicating that the majority of the aggregates were formed by non-reducible covalent bonds. In contrast, we observed that for untreated IFN β -1a, the reduction with DDT resulted in a decrease in dimer content by approximately 60% (Figure 1A), indicating that most of the dimers in the untreated IFN β -1a were formed through disulfide bridging.




Figure 1A. SEC (TSKgel Super SW2000 column) with intrinsic tryptophan fluorescence detection of untreated IFN β -1a before (solid grey chromatogram) and after reduction and alkylation (dashed grey) and oxidized IFN β -1a before (solid black) and after reduction and alkylation (dashed black). The vertical dashed lines show the range of each peak: (1) mainly representing oligomers, (2) dimers, (3) monomers, (4) fragments.

SEC with fluorescence detection of ABS-tagged proteins was used to study whether the monomers or aggregates contain DOPA (3,4-dihydroxyphenylalanine) and/or DOCH (2-amino-3-(3,4-dioxocyclohexa-1,5-dien-1-yl) propanoic acid), produced by oxidation of tyrosine (Tyr) and/or phenylalanine (Phe) residues and subject to fluorogenic derivatization with ABS^[17] and/or 5-hydroxytryptophan, a Trp oxidation product which can also form fluorescent benzoxazole products upon ABS derivatization^[27-28]. Our data show that after derivatization of the oxidized and dialyzed protein with

ABS, the total SEC fluorescence peak area (i.e. the sum of all the peak areas under the curve) for the ABS-derivatized oxidized IFN β -1a is about six fold higher than that of the ABS-derivatized untreated protein (Figure 1B), indicating that MCO of IFN β -1a leads to formation of DOPA/DOCH and/or 5-hydroxytryptophan residues in the oxidized protein.

ABS derivatization of non-oxidized IFN β -1a also produces a weak fluorescent signal mainly associated with protein monomer (Figure 1B), suggesting a background oxidation in the untreated protein.




Figure 1B. SEC (Insulin HMWP Column) with ABS fluorescence detection of ABS-derivatized untreated IFN β -1a (grey) and ABS-derivatized oxidized IFN β -1a (black). The vertical dashed lines show the range of each peak: (1) mainly representing oligomers, (2) dimers and monomers (with this column it is not possible to discriminate dimer from monomer).

The ABS fluorescence of ABS derivatized oxidized and untreated IFN β -1a was also measured by steady-state fluorescence. The results show a seven fold increase in fluorescence intensity for the oxidized protein (Figure 2), which is consistent with the SEC data.




Figure 2. Extrinsic fluorescence emission spectra of ABS-derivatized untreated IFN β -1a (grey), ABS-derivatized oxidized IFN β -1a (black), and oxidized IFN β -1a (dashed black). Spectra represent the average of two batches.

Further structural characterization was performed by CD (Figure 3) and intrinsic steady-state fluorescence measurements (Figure 4). Likely as a result of oxidation and cross-link formation, it was found that the content of alpha helix in oxidized IFN β -1a had decreased, as indicated by the drop in negative CD signal, with a concomitant increase in random coil structure, as indicated by the higher 208/222 nm ratio measured for the oxidized protein (1.041 ± 0.024) as compared with its native counterpart (0.729 ± 0.004) [29-30].




Figure 3. Far-UV CD spectra of untreated IFN β -1a (grey) and oxidized IFN β -1a (black). Spectra represent the average of two batches.

Moreover, a substantial decrease of Trp fluorescence was observed, pointing to chemical modification of Trp residues and/or loss of tertiary structure in general. No shift in the emission maximum was however observed.




Figure 4. Intrinsic steady-state fluorescence of untreated IFN β -1a (grey) and oxidized IFN β -1a (black). Spectra represent the average of two batches.

Mass spectrometry analysis

Undigested IFN β -1a

The data of liquid chromatography coupled to electrospray ionization mass spectrometry (LC-ESI-MS) analysis of undigested untreated IFN β -1a (Figure 5A) are in agreement with previously reported results [31]: the spectrum of the protein represents a mixture of multiple glycoforms (mainly fucosylated and sialylated protein) where the most abundant isoform contains one mono-fucosylated, biantennary structure carrying two sialic acid residues, featuring a total molecular weight of 22376 Da. The spectrum of the oxidized protein represents a single broad peak with a maximum at 22460.5 Da resulting from an overlay of multiple heterogeneously oxidized protein isoforms (Figure 5B), similar to results published for another oxidized protein [32].




Figure 5A. Deconvoluted mass spectrum of undigested untreated IFN β -1a




Figure 5B. Deconvoluted mass spectrum of undigested oxidized IFN β -1a

Sequence-specific analysis of IFN β -1a oxidative modifications

This section focuses on the identification of amino acid sequence-specific oxidative protein modifications through MS/MS analysis of IFN β -1a digests and the results will be presented in the following order: Methionine (Met), Phe, Histidine (His), Tyr and Trp oxidation. It is noteworthy that some peptide sequences potentially contain more than one modification, and that some MS/MS spectra may represent a mixture of peptide isoforms with the same m/z but different locations of oxidative modifications within the sequence. Table I lists all the chemically modified peptides detected. Although a few modifications were observed also in peptides derived from the untreated protein (Table I, last column), most modifications were observed in peptides from oxidized IFN β -1a and involved Met, Phe, His, Tyr and Trp residues.

Table II shows all the potential targets for MCO, including the ones found oxidized in the present study.

Table I. Chemical modifications measured by LC-ESI-MS/MS in peptides from oxidized and untreated IFN β 1a obtained after reduction, alkylation and enzymic digestion.

Chemical modifications and reference to corresponding mass spectrum	Peptide	Experimental m/z	Charge	Theoretical mass	Δ m	Oxidized IFN β 1a*	Un-treated IFN β 1a*
M ₁ (O) Figure S1	M ₄ SYNLLGFLQR ₁₁	679.35	2	1356.70	0.00	+	+
M ₁ (O), Y ₃ (O) Figure S2	M ₄ SYNLLGFLQR ₁₁	687.35	2	1372.69	+0.01	+	-
Y ₃ (DOCH) Figure S3	M ₄ SYNLLGFLQR ₁₁	678.34	2	1354.68	0.00	+	-
M ₁ (loss CH ₃ S) Figure S4	M ₄ SY NLLGFLQR ₁₁	647.35	2	1292.68	+0.02	+	+
F ₃₈ (O) Figure S5 (a-c)	M ₃₆ NFDIPEIK ₄₅	626.30	2	1250.59	+0.01	+	-

M ₃₆ (O) Figure S6(a-c)	M ₃₆ NFDIPEEIK ₄₅	626.30	2	1250.59	+0.01	+	+
M ₆₂ (O) Figure S7	M ₆₂ LQNIFAIFR ₇₁	634.84	2	1267.68	0.00	+	-
M ₆₂ (loss CH ₃ S) Figure S8	M ₆₂ LQNIFAIFR ₇₁	402.23	3	1203.68	+0.01	+	-
M ₁₁₇ (O), H ₁₂₁ (O) Figure S9	L ₁₁₆ MSSLHLK ₁₂₃	480.76	2	959.52	0.00	+	-
F ₅₀ (O), Q(deamidation in several positions) Figure S10	Q ₄₆ LQQFQK ₅₂	468.76	2	935.48	+0.04	+	-
H ₉₃ (O) Figure S11	N ₈₆ LLANVYHQINHLK ₉₉	846.96	2	1691.92	0.00	+	-
H ₉₇ (O) Figure S12	N ₈₆ LLANVYHQINHLK ₉₉	846.96	2	1691.92	0.00	+	-
H ₉₃ (O), H ₉₇ (O) Figure S13	N ₈₆ LLANVYHQINHLK ₉₉	854.96	2	1707.91	+0.01	+	-

H ₉₃ (asn) Figure S14(a-b)	N ₈₆ LLANVYHQINHLK ₉₉	827.46	2	1652.91	+0.01	+	-
H ₉₇ (asn) Figure S15(a-b)	N ₈₆ LLANVYHQINHLK ₉₉	827.46	2	1652.91	+0.01	+	-
H ₁₃₁ (O), Y ₁₃₂ (O) Figure S16(a-c)	I ₁₂₉ LHLYLK ₁₃₄	401.74	2	801.48	0.00	+	-
Y ₁₃₈ (DOCH), H ₁₄₀ (O) Figure S17	E ₁₃₇ YSHCAWTIVR ₁₄₇	697.81	2	1393.62	0.00	+	-
H ₁₄₀ (O), C141(IAM)# Figure S18	Y ₁₃₈ SHCAWTIVR ₁₄₇	654.81	2	1307.62	0.00	+	-
W ₂₂ (O), N ₂₅ (deamidation) Figure S19	L ₂₀ LWQLNGR ₂₇	508.78	2	1015.55	+0.01	+	+
W ₂₂ (N-fkyn), N ₂₅ (deamidation) Figure S20	L ₂₀ LWQLNGR ₂₇	516.78	2	1031.55	+0.01	+	+

* + detected; - not detected

#(IAM): alkylation with iodoacetamide

Table II. Oxidation prone amino acid residues and oxidized amino acids detected in peptides derived from oxidized IFN β -1a.¹

Methionine	Phenylalanine	Tyrosine	Tryptophan	Histidine
1	<i>8</i>	3	22	93*
36	<i>15</i>	<i>30</i>	<i>79#</i>	97*
62	<u>38</u>	<i>60</i>	<i>143#</i>	<u>121*</u>
117	50	<i>92</i>		131
	<i>67</i>	<u>125</u>		140
	<i>70#</i>	<u>126</u>		
	<i>111</i>	<u>132</u>		
	<i>154#</i>	138		
	<i>156</i>	<i>155</i>		
		<i>163</i>		

¹ Bold numbers: oxidized residues; bold underlined numbers: oxidized residues involved in H-bond critical for the correct folding of IFN β -1a; underlined numbers: residues involved in H-bond critical for the correct folding of IFN β -1a (Karpusas et al. [7]); plain italic numbers: non-oxidized residues.

Hydrophobic residues that stabilize the core of the molecule.

* Residues that coordinate a zinc ion, responsible for dimer formation.

A supplementary Table S1 (available online on Molecular Pharmaceutics) shows all the potential amino acid modifications included in the settings of a database search for oxidized, reduced, alkylated and digested IFN β -1a samples. All annotated MS/MS spectra for oxidative protein modifications along with suggested peptide structures presented as inserts are shown in the supplementary Figures S1-S20 (available on line on Molecular Pharmaceutics). Note that in the supplementary figures, the peptide structures of the non-modified amino acid residues are displayed in a one-letter code, while the respective full structures are drawn for the suggested oxidatively modified and alkylated/deamidated residues.

Methionine oxidation

Met1 has been found susceptible to oxidation already by other authors [7, 31]. The b₂⁺ ion in Figure S1, where the peptide M₁SYNLLGFLQR₁₁ is displayed, shows the incorporation of one oxygen atom (+16 Da) into the sequence

Met1Ser2: here, Ser is less prone to oxidation than Met, hence the target of oxidation is likely Met1. Figure S2 shows the same peptide with two oxygen atoms incorporated (+32 Da), which may represent a mixture of two sequences where either Met1 is oxidized to its sulfone, or DOPA (formed from Tyr3) and Met sulfoxide are present together. This is illustrated in the inserts to Figure S2, showing two potential b_{2+} ions, one with a mass increase of +16 Da (mono oxidized, indicated as Met ox) and another with the mass increase of +32 Da (di-oxidized, indicated as Met (ox)₂). The second insert shows two fragments with m/z 1123.57 and 1139.25, which may represent the y_{9+} ions for the unmodified and oxidized form of Tyr3; the ratio of these peaks suggests that the peptide containing oxidized Met1 and DOPA in position 3 is far less abundant than the unmodified peptide (a fraction of less than 10%).

However, this value does not necessarily reflect a lower rate of DOPA formation compared to Met sulfone; rather, it may indicate a higher reactivity of DOPA, resulting in DOCH and further cross-linked products. A spectrum of the doubly charged peptide ion with m/z 678.34 in Figure S3 shows such an example where Tyr is oxidized to DOCH based on a mass increase of 14 Da, which corresponds to the incorporation of one oxygen atom and loss of two hydrogen atoms, albeit at very low abundance of both y_{9+} and b_{3+} -H₂O sequence-indicating ions.

We were also able to detect a characteristic loss of methane sulfenic acid (CH₃SOH, -64 Da, compared with the mono oxidized sequence) from the N-terminus oxidized Met (Figure S4), which was suggested earlier as diagnostic for identifying peptides containing oxidized Met [26, 33].

Met36 is located in a solvent exposed domain of IFN β -1a [7, 31]. Figure S5a and S5b represent the MS/MS spectra matching the sequence M₃₆NFDIPEEIK₄₅, in which either Met36 or Phe38 is oxidized. These two products are not resolved by our HPLC method and the respective spectra overlay, as evidenced by the presence of two potential fragment ions for y_{8+} at m/z 990.48 and 1006.44 (Figure S5b) for oxidized Met36 and oxidized Phe38, respectively. As additional evidence for oxidized Phe38, the ion at m/z 228.18 can be considered, which most likely represents the b_{2+} -H₂O ion (indicated as F ox) from the parent peptide with oxidized Phe38 (Figure S5c). Though the fraction of the peptide with oxidized Phe38 is rather small (ca. 3-5% based on the relative abundance of fragment ion y_{8+} in Figure S5b, indicated as F ox), it

is noteworthy that in the control spectra (non-oxidized IFN β -1a) both fragments at 1006.44 and at 228.18 were not observed (Figure S6a-S6c). Altogether, these data suggest that untreated IFN β -1a already contains some oxidized Met36 residues, whereas oxidized Phe38 is only present in oxidized IFN β -1a.

Met62 is a buried residue [7, 31]. It was resistant to oxidation by hydrogen peroxide [31], however, in conditions of MCO, we detected MS/MS spectra for the sequence M₆₂LQNIFAIFR₇₁ containing the oxidized Met62 (Figure S7). Again, the spectrum for the loss of methane sulfenic acid in position 62, indicative of Met62 oxidation, was observed (Figure S8).

Met117 is a solvent exposed residue [7, 31] and is most susceptible to oxidation (under mild oxidative conditions via hydrogen peroxide), as compared to Met1, Met36 and Met62 [31]. Figure S9 represents a spectrum for the sequence L₁₁₆MSSLHLK₁₂₃, where besides Met117, His121 is oxidized to 2-oxo-His. The distinct b₂⁺ and y₃⁺ ions indicate oxidation of Met117 and His121, respectively.

Phenylalanine oxidation

The fragment containing oxidized Phe38 (M₃₆NF₃₈DIPEEIK₄₅) has been described above in the section Methionine oxidation.

Phe50 is adjacent to several Gln residues, which may undergo deamidation, during digestion or MCO. Figure S10 presents a typical MS/MS spectrum indicating the oxidation of Phe50, in addition to deamidation of one of the Gln residues. Formation of pyroglutamic acid, which should be attributed only to the cyclization of N-terminal Gln in the peptide (-18 Da) during the LC-MS analysis, was also detected.

Histidine and tyrosine oxidation

His oxidation to 2-oxo-His is well documented and has been measured in proteins such as insulin [34-36]. Stadtman et al. showed that His oxidation also can yield asparagine as a potential product [37].

The sequence N₈₆LLANVYHQINHLK₉₉ obtained after digestion with a combination of trypsin and endoproteinase Glu-C, contains two His residues in positions 93 and 97 and one Tyr residue in position 92. Several observed

combinations of His93 or His97 mono oxidation (+16 Da on His), oxidation of both His residues (+32 Da), and formation of Asn in positions 93 and 97 are shown in Figures S11, S12, S13, S14(a-b), S15(a-b), where the respective modifications are proven by $b7^+$, $b8^+$, and $b12^+$ ions, as well as $y3^+$, $y7^+$, $y8^+$, and $y12^{2+}$ ions. In Figure S15 are shown only the ions which differ from Figure S14.

His121 and Tyr3 oxidation was already demonstrated for the fragments $L_{116}MSSLHLK_{123}$ and $M_1SYNLLGFLQR_{11}$, respectively, as discussed above.

Sequence $I_{129}LHYLK_{134}$ contains two potential sites for oxidation: His131 and Tyr132. The ions highlighted in Figure S16a fit to oxidation of either His131 or

Tyr132, whereas in Figure S16b, based on multiple fragments for the $y4^+$ ion, oxidation of both amino acid residues is suggested. The ions $y4^+-H_2O$ and $b4^+$ in Figure S16b, at m/z 574.26 and m/z 559.29, respectively, support the simultaneous oxidation of His and Tyr. Also, the region of the spectrum between 200 and 400 m/z contains two peaks identified as $b3^+$ in which His (Figure S16b, H ox, m/z 380.28) or Tyr (Figure S16c, Y ox, m/z 364.11) are oxidized. Furthermore, in Figure S16c is depicted the ion $y3^{2+}$ supporting Tyr oxidation. Altogether, it seems that three different peptides containing either oxidized His131, oxidized Tyr132, or both amino acids oxidized, were detected simultaneously.

In the sequence $E_{137}YSHCAWTIVR_{147}$, containing a missed cleavage site and 2 additional oxygen atoms, there are 3 potential oxidation sites: Tyr138, His140, and Trp143. In the spectrum shown in Figure S17 the $y5^+-H_2O$ ion at m/z 656.96 rules out Trp oxidation, $y8^{2+}$ at m/z 501.36, in the insert, supports His oxidation, and $b3^+$ and $b4^{2+}$ are in accordance with Tyr oxidation to DOCH. Further evidence for His140 oxidation is shown in Figure S18, where Cys is derivatized with iodoacetamide, and N-terminal Glu (E) is cleaved-off by Glu-C.

Tryptophan oxidation





Trp22 oxidation was detected in both the oxidized and the control samples, suggesting a spontaneous oxidation of this residue during protein storage or handling. Spectra presented in Figures S19 and S20 show the formation of the major oxidative products, hydroxyl Trp (probably hydroxylated at position 5), and N-formyl kynurenine [38-39], respectively, as evidenced through the

presence of the sequence-indicative ions $y3^+$ - $y7^+$ and some b^+ ions, particularly $b3^+$. In addition to Trp oxidation, Asn25 deamidation was detected in peptide L₂₀LWQLNGR₂₇ from both oxidized and control IFN β -1a, which could be expected given the highly deamidation prone N₂₅G sequence [40].

Cross-links

This section focuses on MS/MS identification of covalent cross-links formed through 1,4- and/or 1,6-type addition to the electrophilic product of Tyr oxidation, i.e. DOCH, resulting from MCO of IFN β -1a. As we have only MS/MS but no NMR data of our reaction products, we have to assume that both reactions are possible. Table III lists all the cross-linked peptides detected by MS/MS and Figures 6a, 7a, 8a and 9a represent the corresponding MS/MS spectra along with the peptide cross-links. The structures displayed in Figures 6b, 7b, 8b and 9b representatively show only the products of 1,4-addition. Data will be presented starting from the first chemically modified electrophilic amino acid measured, i.e. DOCH in the first observed position (Tyr3) of IFN β -1a. Data reported were obtained from IFN β -1a that was oxidized, reduced, alkylated and digested.

Table III. Cross-links measured by LC-ESI-MS/MS in peptides derived from oxidized IFN β -1a after reduction, alkylation and enzymatic digestion (in blue nucleophilic amino acids, in red amino acids oxidized to DOCH).

Cross-link*	Experimental m/z	Charge	Theoretical mass	Δm
 <p>Figure 6</p>	756.02	3	2265.11	-0.05
 <p>Figure 7</p>	756.03	3	2265.11	-0.02
 <p>Figure 8</p>	598.3	2	1194.60	+0.00
 <p>Figure 9</p>	569.79	2	1137.56	+0.02

* (IAM): alkylation with iodoacetamide; (-H₂O): loss of 1 water molecule.

Met1 – Tyr30

The free N-terminus of Met1 is a good nucleophile for 1,4- or 1,6-type addition under our applied conditions (pH 7.2), where the N-terminal amino group is in part deprotonated. Figure 6a shows the MS/MS spectrum corresponding with the cross-link between Met1 and Tyr30 in the respective tryptic peptides, as illustrated by the scheme in Figure 6b. The series of y-ions in the peptide A (where the prefix A indicates the ions that belong to the peptide M₁SYNLLGFLQR₁₁) of the cross-link (Ay²⁺ to Ay⁹⁺) together with Ab¹⁺ in the lower insert (zoomed region m/z 1046 -1060) demonstrate that the

peptide A is linked to peptide B through the Met1 amino group, whereas Bb1⁺-H₂O and Bb1⁺-NH₃ ions (zoomed m/z region 1498-1514) indicate the involvement of Tyr30 of the peptide B in the cross-link formation. Note that in the sequence Y₃₀CLKDR₃₅ both Cys and Lysine (Lys) residues are in alkylated form (displayed by the mass of the parent peptide and fragment ion Bb5⁺⁺). Furthermore, we noticed that both Met1 and Tyr3 in the cross-linked peptide are not oxidized, suggesting that the cross-link may protect these residues from oxidation.




Figure 6a. MS/MS spectrum for the sequence M₁SYNLLGFLQR₁₁ cross-linked through Met1 to the sequence Y₃₀C^(IAM)LK^(IAM)DR₃₅.




Figure 6b. Suggested chemical structure of the cross-linked sequence (theoretical *mass* 2265.11, experimental *m/z* 756.02, $[M+H]^{3+}$, Δm from parent peptide -0.05).

Met1 – Tyr60

Figure 7a, reports the MS/MS spectrum for the cross-link involving Met1 and Tyr60. The structure provided in Figure 7b, where Met1 is covalently bound to Tyr60, was drawn for the position 6 of the aromatic ring of DOPA (or DOCH), which is sterically less hindered than the positions 1 and 2. In the peptide $M_1SYNLLGFLQR_{11}$, an additional mass shift of +16 should be attributed to Tyr3 oxidation to DOPA, as suggested by the presence of ion $Ab3^{2+}$, ruling out the oxidation of another sensitive residue, Phe8. The ion $Ab2^+$ supports the structure shown in Figure 7b. In addition, fragments matching ions $Ay9^+$ and $Bb3^+$ disprove the involvement of sequences $Y_3NLLGFLQR_{11}$ and $D_{54}AA_{56}$ in the cross-link formation.




Figure 7a. MS/MS spectrum of sequence M₁SYNLLGFLQR₁₁ cross-linked through Met1 to the sequence D₅₄AALTIY₆₀E₆₁.




Figure 7b. Suggested chemical structure of the cross-linked sequence (theoretical *mass* 2265.11, experimental *m/z* 756.03, $[M+H]^3+$, Δm from parent peptide -0.02).

Lys105 - Phe111

Figure 8a displays the MS/MS spectrum consistent with a cross-link between Lys105 and Phe111. It must be noticed that the mass for this cross-link is 18 Da lower than the mass that would be expected. This is due to loss of water on Glu109 in the sequence $K_{108}EDFTR_{113}$, which can arise from the cyclization with its N-terminal amino group or with the more nucleophilic amino group of Lys108, which would lead to the formation of a 1,4 diazocine-like structure as shown by Koriatopoulou et al [41]. The presence of an intense fragment ion $Bb1^{++}$ in particular shows that the sequence $K_{108}EDFTR_{113}$ is covalently attached to Lys105, as illustrated in Figure 8b. Furthermore, the fragment ion $By2^+$ proves that neither Leu106 nor Glu107 of the sequence $K_{105}LE_{107}$ are involved in the cross-linked structure.




Figure 8a. MS/MS spectrum of sequence $K_{105}LE_{107}$ cross-linked through Lys105 to the sequence $K_{108}E^{(-H_2O)}DF_{111}TR_{113}$.




Figure 8b. Suggested chemical structure of the cross-linked sequence (theoretical *mass* 1194.60, experimental *m/z* 598.30, $[M+H]^{2+}$, Δm from parent peptide +0.00).

Lys105 – Tyr126

The cross-linked sequence $R_{124}YYGR_{128}$ with $K_{105}LE_{107}$ through Lys105 and Tyr126 is presented in Figure 9. Here there are two adjacent Tyr residues (in $R_{124}YYGR_{128}$) which can be involved in the cross-link. The $Ay3^{++}$ and $Ay4^{++}$ related ions however suggest that Tyr126 (and not Tyr125) serves as electron acceptor in the cross-link. $[Bb1 + Na]^+$ and $[Bb2 + Na]^+$ fragments prove the involvement of Lys105 in the peptide cross-linking. The sodiation of the respective fragment ions (except for $By2^+$) is due to complex formation between the C-terminal carboxyl of Arg128 and residual sodium ions present in samples, likely due to incomplete removal of sodium phosphate buffer during protein dialysis after MCO.




Figure 9a. MS/MS spectrum of sodiated sequence $K_{105}LE_{107}$ linked through Lys105 to the sequence $R_{124}YY_{126}GR_{128}$ (the inset show the MS/MS spectrum zoomed in the m/z range 415-428).




Figure 9b. Suggested chemical structure of the cross-linked sequence (theoretical $mass$ 1137.56, experimental m/z 569.79, $[M+H]^{2+}$, Δm from native parent peptide +0.02).

Discussion

Oxidative chemical modification of amino acid residues may alter the secondary and tertiary protein structure, favoring interaction between protein surfaces and subsequently leading to non-covalent aggregation. Indeed, MCO (using the oxidative system presented in this paper) of proteins, such as growth hormone [42], IFN α -2b [14], IFN β -1a [8], IgG1 [16], IgG2 [43], insulin and PEGylated insulin [19], relaxin [44], recombinant SHa (29–231) prion protein [45], and superoxide dismutase [46], have been shown to lead to extensive aggregation. Moreover, protein aggregates generated by MCO have been shown to be particularly immunogenic.

For instance, Hermeling et al. [14–15], using a transgenic immune tolerant mouse model, discovered that aggregated IFN α -2b, oxidized via metal catalysis was more immunogenic than IFN α -2b aggregates that were produced otherwise.

More recently, van Beers and colleagues hypothesized that a particular combination of oxidation and covalent aggregation could be responsible for the immune response against IFN β -1a exposed to MCO, though no particular mechanisms for chemical cross-linking were demonstrated [8]. Similarly, MCO of an IgG1 was found to produce immunogenic aggregates [16].

Here, performing an extensive mass spectrometric characterization of IFN β -1a oxidized under conditions identical to those in the above examples (i.e., Cu²⁺/ascorbate catalysis), we describe chemical modifications of multiple residues that can affect the structure of IFN β -1a. Results of the current study, in particular, reveal that the oxidative modification of Phe and Tyr results in an electron acceptor structure, namely DOCH, which may be involved in IFN β -1a cross-linking through a 1,4- or 1,6-type addition mechanism of primary amines to DOCH. The results reported in this work are in agreement with the data we recently published using insulin as a model protein [17]. However, since Met and Trp are not present in insulin, we did not know whether these are involved in covalent cross-linking of other proteins such as IFN β -1a. Although we detected oxidation of 4 Met residues and 1 Trp residue in oxidized IFN β -1a, we found no evidence of Met or Trp being involved in covalent cross-links. These data are in contrast with the common opinion that Trp oxidation could lead to new carbonyl groups and subsequent cross-linking via Schiff base formation [47]. However, the imine structure generated through

Schiff base formation is reversible unless it is reduced with sodium borohydride or cyanoborohydride to form a secondary amine group [48], which may explain why Trp oxidation did not seem to be involved in aggregation of IFN β -1a.

Our data on ABS derivatization of the control samples (Figure 1B) support the hypothesis that DOCH is an intermediate in the covalent cross-links of IFN β -1a aggregates induced by MCO. SEC analysis under reducing conditions did not point to disulfide-mediated covalent cross-links. Furthermore, fluorescence spectroscopy data and MS/MS analysis helped to exclude other potential mechanisms of aggregation, such as dityrosine formation. This suggests that the reaction between two tyrosyl radicals is not favorable under our experimental conditions [49].

In addition to the putative cross-links via a 1,4- or 1,6-type addition mechanism, extensive oxidative modifications of numerous amino acid residues were induced during MCO: Met in positions 1, 36, 62 and 117 were found to be oxidized to sulfoxides. Met1 was also oxidized to a higher oxidation state to form Met sulfone. His oxidation to 2-oxo-His, as observed before in insulin and other proteins exposed to similar oxidative conditions [50], targeted IFN β -1a residues in positions 93, 97, 121, 131 and 140. Moreover, oxidative modification to Asn was detected for His93 and His97.

Unfortunately, we failed to detect reliable spectra for ABS-derivatized peptides derived from oxidized IFN β -1a (unpublished data). This could be attributed to either relatively low abundance of such modifications or further chemical reactions, which may occur during the analysis, thus interfering with the detection based on a mass increase of 179, 196 and 366 Da [27].

Table II demonstrates that not all of the potential targets for MCO were found oxidized. Most of the unmodified amino acids, such as Phe70, Trp79 and Tyr125, are in fact residues which are responsible for stabilizing the hydrophobic core of the molecule through a broad network of hydrogen bonds [7]. This could protect them from MCO and chemical cross-linking. A similar explanation could be given for the relatively low number of detected cross-linked peptides, which is far below the theoretically possible number of cross-links.

Besides the chemical modifications discussed above, based on far-UV CD measurements we noticed that MCO leads to changes in IFN β -1a's secondary

structure resulting in the conversion of alpha helices to disordered structures [29, 51]. Interestingly, this was also seen upon MCO of IFN α -2b [14], but not of IgG1, which has only minor alpha helical content and for which its beta-sheet content seemed to be largely maintained after MCO [16]. Nevertheless, MCO of IgG1 did result in immunogenic aggregates [16], comparable to the observations with IFN α -2b and IFN β -1a. This suggests that the change in secondary structure in oxidized IFN α -2b and IFN β -1a is not a major factor contributing to the immunogenicity of these products. Rather, the combination of covalent aggregation and chemical modifications, which are probably very similar across the different proteins, likely contribute to the immunogenicity of proteins exposed to MCO. The structural changes observed in the present study, i.e. oxidation, conformational changes and aggregation, are comparable to the ones previously measured in IFN α -2b, although at that time a detailed MS/MS analysis was not performed and only Met oxidation was investigated [14]. However, recently DOPA formation in IFN α -2b was measured by our group (unpublished data), and, considering that both interferons share similar structural features, we suggest that the same type of chemical modifications and cross-links could be expected in IFN α -2b.

Conclusion

In this work we mapped the modifications of the primary structure in oxidized and immunogenic aggregates of IFN β -1a, focusing on the amino acids potentially involved in covalent cross-linking. Several oxidative modifications were identified, especially in oxidation prone solvent-exposed amino acids. The primary role of DOPA and DOCH, i.e. Tyr and Phe oxidation products, as electron acceptors for 1,4- or 1,6-type addition, has been confirmed. These results are in agreement with the mechanistic studies previously performed on insulin, and potentially might be extended to other proteins exposed to similar oxidative conditions.

Acknowledgements

The authors thank Dr. Nadya Galeva for performing MS measurements, The University of Kansas and the National Institutes of Health (PO1AG12993) for financial support, and Leiden University Fund/Slingelands (LUF, 1111/19-4-

11\O, SI) and Nederlandse Stichting voor Farmacologische Wetenschappen (NSFW) for travel grants to Riccardo Torosantucci.

References

- [1] C. Kaynor, M. Xin, J. Wakefield, J. Barsoum, X. Q. Qin. Direct evidence that IFN-beta functions as a tumor-suppressor protein. *J. Interferon Cytokine Res.* **2002**, *22*, 1089-1098.
- [2] P. A. Calabresi. Diagnosis and management of multiple sclerosis. *Am. Fam. Physician* **2004**, *70*, 1935-1944.
- [3] L. Runkel, W. Meier, R. B. Pepinsky, M. Karpusas, A. Whitty, K. Kimball, M. Brickelmaier, C. Muldowney, W. Jones, S. E. Goelz. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). *Pharm. Res.* **1998**, *15*, 641-649.
- [4] I. Nelissen, E. Martens, P. E. Van Den Steen, P. Proost, I. Ronsse, G. Opdenakker. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. *Brain* **2003**, *126*, 1371-1381.
- [5] Y. Kagawa, S. Takasaki, J. Utsumi, K. Hosoi, H. Shimizu, N. Kochibe, A. Kobata. Comparative-Study of the Asparagine-Linked Sugar Chains of Natural Human Interferon-Beta-1 and Recombinant Human Interferon-Beta-1 Produced by 3 Different Mammalian-Cells. *J. Biol. Chem.* **1988**, *263*, 17508-17515.
- [6] H. S. Conradt, H. Egge, J. Peter-Katalinic, W. Reiser, T. Siklosi, K. Schaper. Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line. *J. Biol. Chem.* **1987**, *262*, 14600-14605.
- [7] M. Karpusas, M. Nolte, C. B. Benton, W. Meier, W. N. Lipscomb, S. Goelz. The crystal structure of human interferon beta at 2.2-angstrom resolution. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 11813-11818.
- [8] M. M. van Beers, M. Sauerborn, F. Gilli, V. Brinks, H. Schellekens, W. Jiskoot. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. *Pharm. Res.* **2011**, *28*, 2393-2402.
- [9] M. M. van Beers, M. Sauerborn, F. Gilli, V. Brinks, H. Schellekens, W. Jiskoot. Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice. *Pharm. Res.* **2010**, *27*, 1812-1824.
- [10] R. A. Rifkin, E. T. Maggio, S. Dike, D. A. Kerr, M. Levy. n-Dodecyl-beta-d-Maltoside Inhibits Aggregation of Human Interferon-beta-1b and Reduces Its Immunogenicity. *J. Neuroimmune Pharmacol.* **2011**, *6*, 158-162.
- [11] M. B. Seefeldt, M. S. Rosendahl, J. L. Cleland, L. K. Hesterberg. Application of high hydrostatic pressure to dissociate aggregates and refold proteins. *Curr. Pharm. Biotechnol.* **2009**, *10*, 447-455.

- [12] A. Bertolotto, S. Malucchi, A. Sala, G. Orefice, P. B. Carrieri, M. Capobianco, E. Milano, F. Melis, M. T. Giordana. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. *J. Neurol. Neurosurg. Psychiatry* **2002**, *73*, 148-153.
- [13] C. Scagnolari, F. Bellomi, O. Turriziani, F. Bagnato, V. Tomassini, V. Lavalpe, M. Ruggieri, F. Bruschi, G. Meucci, G. Dicunzio, G. Antonelli. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. *J. Interferon Cytokine Res.* **2002**, *22*, 207-213.
- [14] S. Hermeling, L. Aranha, J. M. A. Damen, M. Slijper, H. Schellekens, D. J. A. Crommelin, W. Jiskoot. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. *Pharm. Res.* **2005**, *22*, 1997-2006.
- [15] S. Hermeling, H. Schellekens, C. Maas, M. F. Gebbink, D. J. Crommelin, W. Jiskoot. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. *J. Pharm. Sci.* **2006**, *95*, 1084-1096.
- [16] V. Filipe, W. Jiskoot, A. H. Basmeleh, A. Halim, H. Schellekens. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. *MAbs* **2012**, *4*, 740-752.
- [17] R. Torosantucci, O. Mozziconacci, V. Sharov, C. Schöneich, W. Jiskoot. Chemical Modifications in Aggregates of Recombinant Human Insulin Induced by Metal-Catalyzed Oxidation: Covalent Cross-Linking via Michael Addition to Tyrosine Oxidation Products. *Pharm. Res.* **2012**, *29*, 2276-2293.
- [18] C. Gallo-Rodriguez, X. D. Ji, N. Melman, B. D. Siegman, L. H. Sanders, J. Orlina, B. Fischer, Q. Pu, M. E. Olah, P. J. van Galen, et al. Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. *J. Med. Chem.* **1994**, *37*, 636-646.
- [19] R. Torosantucci, B. Kükroer, A. Mero, M. Van Winsen, R. Tantipolphan, W. Jiskoot. Plain and mono-pegylated recombinant human insulin exhibit similar stress-induced aggregation profiles. *J. Pharm. Sci.* **2011**, *100*, 2574-2585.
- [20] C. Giulivi, K. J. Davies. Dityrosine: a marker for oxidatively modified proteins and selective proteolysis. *Methods Enzymol.* **1994**, *233*, 363-371.
- [21] K. Ikehata, T. G. Duzhak, N. A. Galeva, T. Ji, Y. M. Koen, R. P. Hanzlik. Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo. *Chem. Res. Toxicol.* **2008**, *21*, 1432-1442.
- [22] H. Xu, M. A. Freitas. A mass accuracy sensitive probability based scoring algorithm for database searching of tandem mass spectrometry data. *BMC Bioinformatics* **2007**, *8*, 133.

- [23] H. Xu, M. A. Freitas. MassMatrix: a database search program for rapid characterization of proteins and peptides from tandem mass spectrometry data. *Proteomics* **2009**, *9*, 1548-1555.
- [24] H. Xu, L. Yang, M. A. Freitas. A robust linear regression based algorithm for automated evaluation of peptide identifications from shotgun proteomics by use of reversed-phase liquid chromatography retention time. *BMC Bioinformatics* **2008**, *9*, 347.
- [25] H. Xu, L. Zhang, M. A. Freitas. Identification and characterization of disulfide bonds in proteins and peptides from tandem MS data by use of the MassMatrix MS/MS search engine. *J. Proteome Res.* **2008**, *7*, 138-144.
- [26] B. Paizs, S. Suhai. Fragmentation pathways of protonated peptides. *Mass Spectrom. Rev.* **2005**, *24*, 508-548.
- [27] V. S. Sharov, E. S. Dremina, N. A. Galeva, G. S. Gerstenecker, X. Li, R. T. Dobrowsky, J. F. Stobaugh, C. Schöneich. Fluorogenic Tagging of Peptide and Protein 3-Nitrotyrosine with 4-(Aminomethyl)-benzenesulfonic Acid for Quantitative Analysis of Protein Tyrosine Nitration. *Chromatographia* **2010**, *71*, 37-53.
- [28] V. S. Sharov, E. S. Dremina, J. Pennington, J. Killmer, C. Asmus, M. Thorson, S. J. Hong, X. Li, J. F. Stobaugh, C. Schöneich. Selective fluorogenic derivatization of 3-nitrotyrosine and 3,4-dihydroxyphenylalanine in peptides: a method designed for quantitative proteomic analysis. *Methods Enzymol.* **2008**, *441*, 19-32.
- [29] C. E. Bobst, R. R. Abzalimov, D. Houde, M. Kloczewiak, R. Mhatre, S. A. Berkowitz, I. A. Kaltashov. Detection and characterization of altered conformations of protein pharmaceuticals using complementary mass spectrometry-based approaches. *Anal. Chem.* **2008**, *80*, 7473-7481.
- [30] S. M. Kelly, T. J. Jess, N. C. Price. How to study proteins by circular dichroism. *Biochim. Biophys. Acta* **2005**, *1751*, 119-139.
- [31] S. Orru, A. Amoresano, R. Siciliano, R. Napoleoni, O. Finocchiaro, A. Datola, E. De Luca, A. Sirna, P. Pucci. Structural analysis of modified forms of recombinant IFN-beta produced under stress-simulating conditions. *Biol. Chem.* **2000**, *381*, 7-17.
- [32] V. S. Sharov, N. A. Galeva, E. S. Dremina, T. D. Williams, C. Schöneich. Inactivation of rabbit muscle glycogen phosphorylase b by peroxynitrite revisited: does the nitration of Tyr613 in the allosteric inhibition site control enzymatic function? *Arch. Biochem. Biophys.* **2009**, *484*, 155-166.
- [33] R. A. J. O'Hair, G. E. Reid. Neighboring group versus cis-elimination mechanisms for side chain loss from protonated methionine, methionine sulfoxide and their peptides. *Eur. J. Mass Spectrom.* **1999**, *5*, 325-334.
- [34] R. Z. Cheng, S. Kawakishi. Site-specific oxidation of histidine residues in glycosylated insulin mediated by Cu²⁺. *Eur. J. Biochem.* **1994**, *223*, 759-764.
- [35] V. Sadineni, C. Schöneich. Selective oxidation of Zn²⁺ - Insulin catalyzed by Cu²⁺. *J. Pharm. Sci.* **2007**, *96*, 1844-1847.

- [36] S. W. Hovorka, H. Biesiada, T. D. Williams, A. Huhmer, C. Schöneich. High sensitivity of Zn-2+ insulin to metal-catalyzed oxidation: Detection of 2-oxo-histidine by tandem mass spectrometry. *Pharm. Res.* **2002**, *19*, 530-537.
- [37] E. R. Stadtman. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. *Annu. Rev. Biochem.* **1993**, *62*, 797-821.
- [38] L. B. Anderson, M. Maderia, A. J. Ouellette, C. Putnam-Evans, L. Higgins, T. Krick, M. J. MacCoss, H. Lim, J. R. Yates, 3rd, B. A. Barry. Posttranslational modifications in the CP43 subunit of photosystem II. *Proc. Natl. Acad. Sci. U. S. A.* **2002**, *99*, 14676-14681.
- [39] S. W. Taylor, E. Fahy, J. Murray, R. A. Capaldi, S. S. Ghosh. Oxidative post-translational modification of tryptophan residues in cardiac mitochondrial proteins. *J. Biol. Chem.* **2003**, *278*, 19587-19590.
- [40] G. Palmisano, M. N. Melo-Braga, K. Engholm-Keller, B. L. Parker, M. R. Larsen. Chemical Deamidation: A Common Pitfall in Large-Scale N-Linked Glycoproteomic Mass Spectrometry-Based Analyses. *J. Proteome Res.* **2012**, *11*, 1949-1957.
- [41] K. Koriatopoulou, N. Karousis, G. Varvounis. Novel synthesis of the pyrrolo[2,1-c][1,4]benzodiazocine ring system via a Dieckmann condensation. *Tetrahedron* **2008**, *64*, 10009-10013.
- [42] S. W. Hovorka, J. Y. Hong, J. L. Cleland, C. Schöneich. Metal-catalyzed oxidation of human growth hormone: Modulation by solvent-induced changes of protein conformation. *J. Pharm. Sci.* **2001**, *90*, 58-69.
- [43] Q. Z. Luo, M. K. Joubert, R. Stevenson, R. R. Ketchem, L. O. Narhi, J. Wypych. Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions. *J. Biol. Chem.* **2011**, *286*, 25134-25144.
- [44] S. Li, T. H. Nguyen, C. Schöneich, R. T. Borchardt. Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. *Biochemistry* **1995**, *34*, 5762-5772.
- [45] J. R. Requena, D. Groth, G. Legname, E. R. Stadtman, S. B. Prusiner, R. L. Levine. Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein. *Proc. Natl. Acad. Sci. U. S. A.* **2001**, *98*, 7170-7175.
- [46] R. Rakhit, P. Cunningham, A. Furtos-Matei, S. Dahan, X. F. Qi, J. P. Crow, N. R. Cashman, L. H. Kondejewski, A. Chakrabartty. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. *J. Biol. Chem.* **2002**, *277*, 47551-47556.
- [47] N. Rauniyar, L. Prokai. Detection and identification of 4-hydroxy-2-nonenal Schiff-base adducts along with products of Michael addition using data-dependent neutral loss-driven MS3 acquisition: method evaluation through an in vitro study on cytochrome c oxidase modifications. *Proteomics* **2009**, *9*, 5188-5193.
- [48] C. Dohno, A. Okamoto, I. Saito. Stable, specific, and reversible base pairing via Schiff base. *J. Am. Chem. Soc.* **2005**, *127*, 16681-16684.

- [49] Y. Kato, N. Kitamoto, Y. Kawai, T. Osawa. The hydrogen peroxide/copper ion system, but not other metal-catalyzed oxidation systems, produces protein-bound dityrosine. *Free Radic. Biol. Med.* **2001**, *31*, 624-632.
- [50] C. Schöneich. Mechanisms of metal-catalyzed oxidation of histidine to 2-oxo-histidine in peptides and proteins. *J. Pharm. Biomed. Anal.* **2000**, *21*, 1093-1097.
- [51] N. Greenfield, G. D. Fasman. Computed circular dichroism spectra for the evaluation of protein conformation. *Biochemistry* **1969**, *8*, 4108-4116.